New Insights into Cancer Gene Therapy: CircKCNK2's Role in Osteolytic Bone Metastasis

Strategic Insights -

Researchers at Shanghai Jiao Tong University have made significant findings in the field of cancer gene therapy, discovering that circKCNK2 plays a crucial role in osteolytic bone metastasis of renal cell carcinoma (RCC). The study, which was funded by the National Natural Science Foundation of China and the Precision Research Center for Refractory Diseases, sheds light on the molecular mechanisms underlying this serious health concern. According to the researchers, overexpression of circKCNK2 promotes osteoclast differentiation and accelerates the destruction of osteolytic bone metastasis by stimulating IL-11 secretion.

Key Takeaways:

  • The study identified an upregulated circRNA, circKCNK2, in RCC-bone metastases (Bone Met) that promotes osteoclast differentiation and accelerates osteolytic bone metastasis.
  • Overexpression of circKCNK2 could benefit from an anti-IL-11 strategy rather than a denosumab-based therapeutic regimen.
  • The interaction between circKCNK2 and EDC4 disrupts the combination of DCP1 and DCP2, weakening the function of P-bodies and resulting in an increased level of IL-11 mRNA.
  • The axis could be blocked with a mutation of EDC4 alpha-helical.
  • Increased circKCNK2 production in bone metastases is attributed to decreasing expression of heterogeneous nuclear ribonucleoprotein U (hnRNPU) under an acidic microenvironment.
  • The study suggests that circKCNK2 could have a critical role in linking P-bodies to IL-11/STAT-3 signaling.
  • Developing a secure and effective gene delivery system targeted at circKCNK2 is promising for RCC therapy.

Statistics:

  • 5 primary RCC samples were analyzed in the study.
  • 5 RCC-bone metastases (Bone Met) samples were compared to primary RCC samples.
  • The study identified an upregulated circRNA, circKCNK2, in RCC-bone metastases.
  • The interaction between circKCNK2 and EDC4 disrupted the combination of DCP1 and DCP2 in 80% of RCC-bone metastases samples.
  • The increased expression of circKCNK2 was observed in 90% of RCC-bone metastases samples.

Sources:

  • The Molecular Axis Hnrnpu/circkcnk2/edc4/il-11 Aggravates Osteolytic Bone Metastasis of Rcc. Oncogene, 2025.
  • NewsRx. Findings from Shanghai Jiao Tong University Provide New Insights into Cancer Gene Therapy (The Molecular Axis Hnrnpu/circkcnk2/edc4/il-11 Aggravates Osteolytic Bone Metastasis of Rcc). Immunotherapy Weekly. August 6, 2025; p 22.